Although molecular typing of HR+/HER2+ breast cancer using transcriptome sequencing provides a comprehensive framework for understanding the tumor’s complex biology and developing targeted treatment strategies for each subtype, its widespread clinical application remains limited. Here, ERBB2 is linked to breast cancer.